Browse by author
Lookup NU author(s): Dr Jess Dyson,
Professor Quentin AnsteeORCiD,
Dr Stuart McPhersonORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Non-alcoholic fatty liver disease (NAFLD) affects up to a third of the population in many developed countries. Between 10% and 30% of patients with NAFLD have non-alcoholic steatohepatitis (NASH) that can progress to cirrhosis. There are metabolic risk factors common to both NAFLD and cardiovascular disease, so patients with NASH have an increased risk of liver-related and cardiovascular death. Management of patients with NAFLD depends largely on the stage of disease, emphasising the importance of careful risk stratification. There are four main areas to focus on when thinking about management strategies in NAFLD: lifestyle modification, targeting the components of the metabolic syndrome, liver-directed pharmacotherapy for high risk patients and managing the complications of cirrhosis.
Author(s): Dyson JK, Anstee QM, McPherson S
Publication type: Review
Publication status: Published
Journal: Postgraduate Medical Journal
Print publication date: 01/02/2015
Online publication date: 22/01/2014
Acceptance date: 01/01/2014
ISSN (print): 0032-5473
ISSN (electronic): 1469-0756
Publisher: BMJ PUBLISHING GROUP